Vor Biopharma Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-62.8M | $-219.6M | $1.72B | $-812.7M | $-1.57B | $-32.5M | $-30.7M | $-27.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $36.0K | $28.0K | $23.0K | $-61.0K | $2.1M | $825.0K | $785.0K | $900.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $9.4M | $8.9M | $7.1M | $8.0M | $1.8M | $1.9M | $1.7M | $2.3M |
| Net Cash from Operating Activities | $-25.4M | $-38.2M | $-22.8M | $-53.7M | $-35.2M | $-31.1M | $-24.1M | $-23.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $120.0K | $48.0K | $314.0K | $244.0K | $152.0K | $231.0K | $72.0K | $34.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-36.5M | $-263.2M | $-49.0M | $-244.0K | $646.0K | $-230.0K | $-72.0K | $-34.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-106.0K | $74.9M | $307.8M | $21.5M | $175.1M | $-606.0K | $53.3M | $41.0K |
| Net Change in Cash | $-62.0M | $-226.6M | $236.0M | $-32.4M | $140.5M | $-31.9M | $29.2M | $-23.3M |
| Free Cash Flow | $-25.5M | $-38.3M | $-23.1M | $-53.9M | $-35.3M | $-31.3M | $-24.1M | $-23.3M |